Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Tumor-targeted transferrin nanoassemblies delivering olaparib and curcumin for combating BCRP-mediated resistance in triple-negative breast cancer.

Created on 16 Nov 2026

Authors

Anam Razzaq, Zhou Dengming, Wang Yue, Naveed Ullah Khan, Asmat Ullah, Haroon Iqbal

Published in

Biomaterials science. Nov 16, 2026. Epub Nov 16, 2026.

Abstract

Triple-negative breast cancer (TNBC) remains clinically difficult to treat, owing to its destructive nature and lack of targeted therapies. To address this challenge, we developed tumor-targeted transferrin (Trf) nanoassemblies for the simultaneous co-delivery of olaparib (Olp) and curcumin (Cur), denoted as Olp-Cur@Trf NAs, aiming to achieve enhanced anticancer efficacy with prolonged blood circulation. The designed nanoassemblies exhibited significantly improved cellular uptake and potent apoptotic activity in TNBC cells. Mechanistically, Cur effectively enhanced the therapeutic potential of Olp against TNBC by downregulating the breast resistance protein (BCRP) expression, thereby blocking Olp efflux and overcoming drug resistance. In in vivo TNBC tumor models, Olp-Cur@Trf NAs demonstrated extended blood circulation and active tumor accumulation, resulting in markedly superior tumor growth inhibition compared to the free drug combination. Importantly, these nanoassemblies were well-tolerated with minimal systemic toxicity, as evidenced by the absence of detectable damage to major organs. Collectively, our results validated the application of Olp-Cur@Trf NAs as a promising and practical therapeutic strategy to reverse BCRP-mediated chemoresistance in TNBC, with significant implications for clinical translation.

PMID:
43037496
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement